BETA
Your AI-Trained Oncology Knowledge Connection!
September 10th 2025
The FDA has assigned a Prescription Drug User Fee Act date of July 11, 2026, for relacorilant as a treatment for platinum-resistant ovarian cancer.
September 4th 2025
Patients with recurrent or metastatic cervical cancer in Hong Kong are now eligible to receive treatment with tisotumab vedotin.
Results from the phase 3 MIRASOL trial led to the approval of mirvetuximab soravtansine for patients with FRα+ ovarian cancer.
July 25th 2025
Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.
July 14th 2025
Among 115 patients treated with avutometinib and defactinib, only 5 deaths occurred in the study, none of which were related to study treatment.